Eli Lilly and Company (NYSE:LLY) Price Target Raised to $805.00 at Morgan Stanley

Eli Lilly and Company (NYSE:LLYFree Report) had its price objective hoisted by Morgan Stanley from $763.00 to $805.00 in a research note released on Wednesday, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Several other equities analysts have also weighed in on LLY. StockNews.com raised Eli Lilly and Company from a hold rating to a buy rating in a report on Friday, November 3rd. Citigroup raised their price objective on Eli Lilly and Company from $525.00 to $675.00 and gave the company a buy rating in a research note on Monday, October 23rd. Cantor Fitzgerald reissued an overweight rating and issued a $630.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 1st. UBS Group reaffirmed a buy rating and set a $710.00 price objective (up from $612.00) on shares of Eli Lilly and Company in a research report on Friday, October 20th. Finally, BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an outperform rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $621.81.

View Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $724.91 on Wednesday. The stock has a market capitalization of $688.16 billion, a PE ratio of 124.98, a P/E/G ratio of 2.24 and a beta of 0.32. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. The business has a fifty day moving average price of $614.01 and a two-hundred day moving average price of $577.12. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $742.00.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the business earned $2.09 EPS. The firm’s revenue was up 28.1% compared to the same quarter last year. As a group, equities analysts predict that Eli Lilly and Company will post 12.73 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Thursday, February 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.72%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 77.93%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 14,388 shares of the business’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the transaction, the insider now directly owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 over the last 90 days. Insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently modified their holdings of the company. Partnership Wealth Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $14,010,000. Avantax Advisory Services Inc. lifted its stake in shares of Eli Lilly and Company by 2.4% in the 4th quarter. Avantax Advisory Services Inc. now owns 37,374 shares of the company’s stock worth $21,786,000 after acquiring an additional 881 shares during the period. Ieq Capital LLC lifted its stake in shares of Eli Lilly and Company by 7.7% in the 4th quarter. Ieq Capital LLC now owns 45,037 shares of the company’s stock worth $26,253,000 after acquiring an additional 3,205 shares during the period. Private Portfolio Partners LLC lifted its stake in shares of Eli Lilly and Company by 1.8% in the fourth quarter. Private Portfolio Partners LLC now owns 2,667 shares of the company’s stock valued at $1,555,000 after purchasing an additional 48 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Eli Lilly and Company by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,395,896 shares of the company’s stock valued at $1,979,508,000 after purchasing an additional 28,104 shares during the period. 81.38% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.